Autologous Cell Therapy for Ischemic Heart Failure

Inclusion Criteria: * Age greater than 18 but less than 80 years * Prior myocardial infarction * Depressed left ventricular ejection fraction (LVEF) ≤ 35% * NYHA functional classification of II to IV Exclusion Criteria: * Not under stable optimal medical management * Cardiac surgery or percutaneous coronary intervention within 3 months * Occurrence of myocardial infarction (MI) within 6 months, in the case of first MI, or 3 months, in the case of any subsequent MI * Prior cell, gene, or transmyocardial laser revascularization therapy * Ventricular wall thickness in target region ≤ 5 mm * Moderate to severe aortic valve stenosis or mechanical valve replacement * Left ventricular aneurysm or thrombus * Left ventricular dysfunction associated with a reversible cause * Vascular disease preventing percutaneous vascular access * History of myopathic disease * History of neoplasia within 5 years, except for basal cell carcinoma * Receiving or planning to receive anti-cancer medications * Serum creatinine \> 3.0 mg/dl * Pregnant, planning to become pregnant, or breastfeeding a child in the next 18 months * Life expectancy of less than 1 year * Morbid obesity (defined as BMI \> 35) * History of bleeding diathesis or coagulopathy * Positive for HIV, Hepatitis B, or Hepatitis C * Known hypersensitivity or contraindication to study product or treatment procedure * Enrolled in another research project at the time of enrollment * Unable to provide informed consent * Unable or unwilling to commit to the follow-up clinical procedures